Lates News

The announcement shows that Iambic Therapeutics, a clinical-stage oncology drug development and technology company in which Nvidia (NVDA.O) holds a stake, completed its U.S. initial public offering, raising $150 million, with the offering price set at the midpoint of its marketed range. Iambic sold approximately 9.38 million shares at $16 per share. A previous filing showed that Iambic had originally set a price range of $15 to $17 per share. Based on the IPO price and the issued shares disclosed in the filing, the company has a market value of $758 million. The filing shows that Iambic uses artificial intelligence and machine learning technologies to develop new therapies. The company will use the proceeds from the IPO to advance three early-stage oncology drug candidates.